Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

Video

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Findings from the first-in-human phase 1 ALPHA study showed a manageable safety profile with the investigational anti-CD19 allogeneic CAR T-cell therapy ALLO-501 in combination with the anti-CD52 monoclonal antibody ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Longer follow-up is needed to assess whether allogeneic CAR T-cell therapy elicits similar efficacy and durability as autologous CAR T-cell therapy, says Neelapu. However, allogeneic CAR T-cell therapy may offer potential advantages over autologous CAR T-cell therapy.

These potential advantages include reduced manufacturing cost, increased accessibility for patients, and lower treatment cost for patients, concludes Neelapu.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD